Market Place
Sourcing Support
Gamida Cell Announces Dosing of 1st Patient in Phase 1/2 Study of GDA-201
10 Aug 2022 //
BUSINESS WIRE
NA to NAM ratio as a biomarker for cell therapy sterility
20 Jul 2022 //
EUROPEANPHARMACEUTICALREVIEW
Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy
09 Nov 2021 //
BUSINESSWIRE
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside
18 Oct 2021 //
BUSINESSWIRE
Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201
02 Mar 2020 //
BUSINESSWIRE
Enforcement Report - Week of August 14, 2019
14 Aug 2019 //
FDA
Enforcement Report - Week of June 19, 2019
19 Jun 2019 //
FDA
Enforcement Report for Week of February 20, 2019
20 Feb 2019 //
FDA
Tru Niagen (Nicotinamide riboside) : ChromaDex vs. Elysium Health
22 Sep 2018 //
PATENT LITIGATION
ChromaDex announces an exclusive worldwide patent license & research agreement
12 Jun 2017 //
GLOBENEWSWIRE
Enforcement Report - Week of March 22, 2017
22 Mar 2017 //
FDA
Laboratoires Colba Inc. Recalls Enerforce Total
22 Feb 2017 //
HEALTH CANADA
Jubilant raises price of Beta Picoline, 3-Cyanopyridine and Vitamin B3 up to 15%
20 Dec 2016 //
PHARMABIZ
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.